Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer

Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]

Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial

It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]

Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial

touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s […]

Deborah Doroshow, ESMO 2020 – COVID-19 and Cancer Outcomes Study (CCOS): Disparities in Cancer during the COVID-19 Pandemic

touchONCOLOGY joins Dr Deborah Doroshow to discuss the recent COVID-19 and Cancer Outcomes Study (CCOS), and how the COVID-19 pandemic has caused disparities in cancer care. Dr Doroshow presented her late-breaking abstract, ‘Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)‘ (LBA74) at the Virtual 2020 ESMO Congress, 19–21 September 2020. […]

Improving Outcomes in Pancreatic Cancer

Oncology & Haematology Review (US). 2020;16(1):59–66 DOI: https://doi.org/10.17925/OHR.2020.16.1.59

Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]

Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets

Oncology & Hematology (US). 2020;16(1):36–42 DOI: DOI: https://doi.org/10.17925/OHR.2020.16.1.36

In 2020, an estimated 147,950 patients will be diagnosed with colorectal cancer (CRC) in the USA, with 53,200 deaths expected.1 While many patients with CRC are cured, metastatic CRC (mCRC) is still a prevalent disease, and systemic therapy options have markedly improved outcomes in patients with unresectable metastatic disease in the last several decades. Cytotoxic […]

Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma

Oncology & Hematology Review (US). 2020; 16(1):12–4 DOI: https://doi.org/10.17925/OHR.2020.16.1.12

Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma.1 Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM,2 MM remains incurable, with a high disease burden.3 Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance.4 An increasing number […]

Development of HER2-targeted Therapies for Gastrointestinal Cancer

European Oncology & Haematology. 2020;16(1):29-38 DOI: https://doi.org/10.17925/EOH.2020.16.1.29

Human epidermal growth factor receptor 2 (HER2) is encoded by a proto-oncogene with important roles in the promotion of cell proliferation, differentiation and angiogenesis via the activation of Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) downstream signalling after it forms homodimers or heterodimers with other HER family members.1–2 HER2 overexpression, […]